Login to Your Account



Forest Gets Late-Stage Antibiotic Through $480M Cerexa Buyout

By Jennifer Boggs


Friday, December 15, 2006
Forest Laboratories Inc. is picking up rights to ceftaroline, a late-stage injectable antibiotic for Gram-positive bacterial infections, through the acquisition of privately held Cerexa Inc. for $480 million in a cash-for-stock transaction. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription